Strategy
Antisense oligonucleotide (ASO)-based therapeutics are becoming more and more popular as evidenced by the recent increase in market approvals and high value partnering transactions. ASOs fill the innovative gap left by more traditional approaches. Recognizing this is what motivated us to develop our 3rd generation antisense platform LNAplus™. Focusing on proof-of-concept, we concentrate on targets that are considered as undruggable by conventional approaches or where we believe that Secarna’s LNAplus™-based ASOs have the potential to demonstrate superior safety and efficacy over other modalities.
For further proof-of-concept, we have established a successful partnership model complementing our molecule design and selection process. In the past, we have engaged in collaborations with internationally renowned centers of excellence across both academia and industry.
Management
Our leadership team consists of biotechnology and pharmaceutical industry experts who are recognized for their contributions in the development of novel antisense therapies and bringing new, safe and efficacious treatments to patients.
Alexander Gebauer
Before joining Secarna as CEO in December 2020, Alexander was CEO and Chairman at Omeicos Ophthalmics Inc, Cambridge, MD, US and served as CDO and Managing Director in the Berlin, Germany based sister company Omeicos Therapeutics GmbH.
Dr. Frank Jaschinski
Frank joined Secarna in 2015 as its Chief Scientific Officer. He is an expert in discovery and development of antisense oligonucleotides.
Career
At Secarna, we enjoy a modern corporate culture and foster an open-minded, diverse and creative work environment in which we like to see our team to contribute and thrive. Together, we work towards our mission to discover and develop the next generation antisense oligonucleotide therapeutics.
We always welcome new ideas, fresh perspectives and look forward to connecting with exceptional scientific talents with a strong entrepreneurial spirit inspired by our company’s mission to discover and develop the next generation antisense oligonucleotide therapeutics.